Anisave develops biologics for companion animals living with cancer. The patient comes first. The science follows.
Anisave is a Canadian companion-animal oncology company, established within the BioFund Universe to give veterinary cancer the dedicated scientific, clinical and commercial focus it deserves.
We are also part of a larger system — BioFund's OneHealth architecture, where companion-animal and human oncology are treated as scientifically connected fields.
Read more about OneHealth →Anisave exists to treat serious cancer in companion animals. The translational science is a product of doing that well.
The Anisave programme is led by its co-inventor, Professor Jim Petrik, from the University of Guelph. The animal hospital on campus sees 2,000 new oncology patients per year — cats and dogs with naturally occurring cancer — with over 6,000 visits annually.
Dr. Petrik has spent more than 20 years developing novel therapies for advanced-stage cancers, with a research focus on the tumour microenvironment and vascular normalization as a strategy to improve therapeutic access to solid tumours. He is the co-inventor of the Anisave programme and the scientist who leads it at the Ontario Veterinary College.
Three simultaneous mechanisms of action. Synergistic by design. Opens access to solid tumours.
Normalises the tumour microenvironment and the abnormal vasculature surrounding solid tumours — reducing hypoxia and interstitial pressure to open therapeutic access for co-administered treatments.
Acts via the CD36/caspase pathway to induce direct tumour cell death — independent of the immune system and independent of vascular access.
Activates and amplifies the immune response against tumour cells. Preclinical studies document NK cell penetration into immunocompetent solid tumour models.
Anisave originated within BioFund's animal health R&D programme — a non-profit research engine developing the next generation of companion-animal biologics. Anisave is the first. More are in active development.
BioFund is selecting one founding strategic partner for Anisave — to help build a category-defining companion-animal oncology company with founding influence, defined rights, and a long-term connection to the OneHealth mission.
Anisave is a proudly Canadian company developing a novel animal oncology therapeutic, led by Professor Jim Petrik. One founding partner will help shape what it becomes.
Anisave has a dedicated mandate, leadership, rights, and development path. It was established to give companion-animal oncology the focused attention a serious medical field deserves.
Anisave is part of BioFund's OneHealth architecture — a system built on the premise that companion-animal and human oncology are scientifically connected, and that the best evidence comes from treating real patients with naturally occurring disease.
Anisave holds exclusive animal oncology rights. The rights are clean, documented, and unambiguous.
Anisave is a proudly Canadian company developing a novel animal oncology therapeutic. The legal structure, the rights, and the development path are established.
Professor Jim Petrik leads translational research at the University of Guelph. The animal hospital on campus sees 2,000 new oncology patients per year — cats and dogs with naturally occurring cancer — with over 6,000 visits annually. The data, the samples, and the clinical insight come from real patients, not engineered models.
Anisave is the first programme to emerge from BioFund's animal health R&D incubator. Caninized cell lines and a tumour organoid testing platform are in active development — building the infrastructure to accelerate the next generation of candidates. The founding partner receives first-look option rights on what the incubator develops next.
The rights structure is simple by design. Anisave holds what it needs to develop and commercialise. BioFund holds what it needs to protect the long-horizon human mission. No overlap, no creep.
Independent in execution. Connected in purpose. Precise in rights.
One founding strategic partner. The conversation begins with capability and conviction.
The founding partner runs the programme — CMC, regulatory strategy, clinical operations, and commercial execution. The expertise and infrastructure to bring a companion-animal biologic to market.
Global or regional commercial infrastructure across the markets that matter for companion-animal therapeutics — with the ability to build Anisave as a focused, standalone oncology brand.
Companion-animal oncology is a serious medical field. The founding partner sees it that way — as a strategic priority deserving a dedicated company, a dedicated team, and a long development horizon.
Anisave is part of BioFund's OneHealth architecture. The founding partner gains a disciplined translational bridge between companion-animal and human oncology — built into the programme by design.
If companion-animal oncology is a strategic priority, we would like to speak. First conversations are straightforward and confidential.
partnerships@anisave.ca